InsiderSignal.AI

InsiderSignal.ai

NUVL - Nuvalent, Inc.

Insider Sale by Balcom Alexandra (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Balcom Alexandra, serving as CFO at Nuvalent, Inc. (NUVL), sold 11,430 shares at $105.21 per share, for a total transaction value of $1,202,527.00. Following this transaction, Balcom Alexandra now holds 85,533 shares of NUVL.

This sale represents a 12.00% decrease in Balcom Alexandra's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Nuvalent, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Balcom Alexandra

CFO

Alexandra Balcom is the Chief Financial Officer (CFO) of Nuvalent, Inc. (NASDAQ:NUVL), a Cambridge, Massachusetts-based precision oncology company focused on developing targeted therapies for lung cancer and other cancers.[[1]](https://www.investing.com/news/insider-trading-news/nuvalent-cfo-balcom-sells-23m-in-nuvl-stock-93CH-4267692)[[2]](https://nuvalent.com/team) She holds an MBA and is a Certified Public Accountant (CPA).[[2]](https://nuvalent.com/team)[[4]](https://investors.nuvalent.com/our-team) As CFO, Balcom oversees the company's financial operations and serves as a director and 10% owner.[[3]](https://www.tradingview.com/news/tradingview:67097567fb0ea:0-nuvalent-cfo-alexandra-balcom-sells-over-7-000-shares/) Balcom recently engaged in insider trading, selling 27,588 shares of Nuvalent Class A Common Stock on September 29-30, 2025, for approximately $2.3 million at prices around $85 per share, after exercising options at $6.89 per share; she retains direct ownership of 61,734 shares.[[1]](https://www.investing.com/news/insider-trading-news/nuvalent-cfo-balcom-sells-23m-in-nuvl-stock-93CH-4267692) Earlier, she sold over 7,000 shares, as reported in SEC filings.[[3]](https://www.tradingview.com/news/tradingview:67097567fb0ea:0-nuvalent-cfo-alexandra-balcom-sells-over-7-000-shares/)[[5]](https://longbridge.com/news/269286760) Her leadership supports Nuvalent's advancements, including the New Drug Application for zidesamtinib and upcoming clinical data presentations.[[1]](https://www.investing.com/news/insider-trading-news/nuvalent-cfo-balcom-sells-23m-in-nuvl-stock-93CH-4267692)

View full insider profile →

Trade Price

$105.21

Quantity

11,430

Total Value

$1,202,527.00

Shares Owned

85,533

Trade Date

Wednesday, April 1, 2026

4 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Nuvalent, Inc.

Company Overview

No company information available
View news mentioning NUVL

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5334163

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime